Sequent Scientific Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financial Signals

Quality Assessment: Mixed Fundamentals with Positive Quarterly Momentum

Sequent Scientific’s quality metrics present a nuanced picture. The company has delivered very positive financial performance in Q2 FY25-26, with net profit surging by 209.15% year-on-year. This marks the seventh consecutive quarter of positive results, signalling consistent operational strength. Profit Before Tax (PBT) excluding other income rose sharply by 246.43% to ₹26.71 crores, while Profit After Tax (PAT) increased by 162.7% to ₹15.97 crores. Return on Capital Employed (ROCE) for the half-year reached a high of 10.65%, indicating efficient capital utilisation in the recent period.

However, the company’s long-term fundamental strength remains weak. Operating profits have declined at a compound annual growth rate (CAGR) of -3.55% over the past five years, reflecting challenges in sustaining growth. Additionally, the average Return on Equity (ROE) stands at a modest 3.90%, suggesting limited profitability per unit of shareholder funds. The high Debt to EBITDA ratio of 8.15 times raises concerns about the company’s ability to service its debt, which could constrain future financial flexibility.

Valuation: Expensive Yet Discounted Relative to Peers

Sequent Scientific’s valuation metrics indicate a premium positioning. The company’s ROCE of 10.2% is accompanied by an Enterprise Value to Capital Employed (EV/CE) ratio of 7.6, signalling an expensive valuation relative to capital employed. Despite this, the stock trades at a discount compared to the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector. Over the past year, the stock price has appreciated by 18.53%, outpacing the BSE500 index, while profits have surged by 128.2%. This disparity results in a high Price/Earnings to Growth (PEG) ratio of 6.6, which may temper enthusiasm among value-focused investors.

Financial Trend: Strong Quarterly Growth Amidst Mixed Long-Term Returns

The recent quarterly results have been a catalyst for the rating upgrade. The company’s net profit growth of over 200% in Q2 FY25-26 and consistent positive results over seven quarters demonstrate a strong upward financial trend. Promoter confidence has also strengthened, with promoters increasing their stake by 9.1% in the last quarter to hold 61.43% of the company’s equity. This stake increase is often interpreted as a vote of confidence in the company’s future prospects.

In terms of returns, Sequent Scientific has delivered consistent outperformance over the medium term. The stock has generated 18.53% returns over the last year, significantly higher than the Sensex’s 8.65% return. Over three years, the stock’s cumulative return of 137.07% dwarfs the Sensex’s 36.79%. However, the five-year return of -4.07% lags the Sensex’s 68.52%, highlighting volatility and challenges in sustaining long-term growth.

Technical Analysis: Shift to Mildly Bullish Momentum

The upgrade to Hold is largely driven by an improvement in technical indicators. The technical trend has shifted from sideways to mildly bullish, reflecting a more positive market sentiment towards the stock. Daily moving averages are mildly bullish, supporting upward price momentum. The stock’s current price stands at ₹205.30, up 6.04% on the day, with a 52-week range between ₹111.00 and ₹260.30.

Weekly and monthly technical indicators present a mixed but improving picture. The Moving Average Convergence Divergence (MACD) is mildly bearish on a weekly basis but bullish monthly, suggesting longer-term momentum is positive despite short-term caution. The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, indicating neither overbought nor oversold conditions. Bollinger Bands are mildly bearish weekly but mildly bullish monthly, further reinforcing the mixed but improving trend.

Other indicators such as the Know Sure Thing (KST) and Dow Theory remain mildly bearish on both weekly and monthly timeframes, signalling some caution. However, the On-Balance Volume (OBV) indicator is bullish monthly, suggesting accumulation by investors. Overall, the technical outlook supports a cautious but optimistic stance, justifying the upgrade from Sell to Hold.

Comparative Performance: Outperforming Sensex and Sector Benchmarks

Sequent Scientific’s stock performance relative to the Sensex and sector benchmarks has been encouraging over recent periods. The stock outperformed the Sensex by 7.4 percentage points over the last year, delivering 18.53% returns compared to the Sensex’s 8.65%. Over three years, the outperformance is even more pronounced, with the stock returning 137.07% against the Sensex’s 36.79%. This consistent outperformance over medium-term horizons highlights the company’s ability to generate shareholder value despite sector headwinds.

Shorter-term returns are more volatile, with a one-month return of -2.49% slightly worse than the Sensex’s -1.98%, and a year-to-date return of -1.37% versus the Sensex’s -2.32%. These fluctuations reflect market volatility and sector-specific challenges but do not detract from the overall positive trend.

Conclusion: Hold Rating Reflects Balanced Outlook Amid Mixed Fundamentals

The upgrade of Sequent Scientific Ltd’s investment rating from Sell to Hold reflects a balanced assessment of the company’s current position. Strong quarterly financial results, rising promoter confidence, and improved technical indicators support a more positive outlook. However, the company’s weak long-term fundamental growth, high debt levels, and expensive valuation metrics temper enthusiasm and justify a cautious stance.

Investors should weigh the company’s recent operational momentum and technical improvements against its structural challenges and valuation concerns. The Hold rating suggests that while the stock is no longer a sell, it may not yet offer compelling value for aggressive buyers. Monitoring upcoming quarterly results and debt servicing capacity will be critical to reassessing the company’s investment potential in the near term.

Unlock special upgrade rates for a limited period. Start Saving Now →